MediGene
Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. With its scientific expertise, Medigene is working on the development of innovative immunotherapies to treat cancer such as T cell receptor-modified T cells (TCR-Ts) or dendritic cell (DC) vaccines in fields of high medical need. The first product candidates are in clinical development and the Company has diverse preclinical programs. Medigene’s strategy is to develop its own therapies towards clinical proof-of-concept, starting with hematological malignancies, and advancing its technologies towards solid tumor indications. In addition, the Company offers selected partners the opportunity to discover and develop additional treatments on the basis of its technological platforms.
 | |
| Type | Stock company |
|---|---|
| MDG1 | |
| Industry | Biotechnology |
| Founded | 1994 |
| Headquarters | Martinsried, Germany |
Key people | Prof Dolores J Schendel (CEO), Dave Lemus (COO), Horst Domdey (Chairman of the supervisory board) |
| Website | www |